we believe the company is structurally more ready than at any point in its recent history. (Source: SGRL Q4 FY26 Concall Transcript, fetched URL, Management Opening Remarks) At 109 Cr revenue and a 730 Cr market cap, SGRL is a micro-cap
5.1 DPP-IV inhibitors The scientific basis for their therapeutic utility in the context of cancer treatment lies in their multifaceted actions on various physiological processes
The drug stays in the body for a long time, so it only needs to be taken once a week
Wegovy, fabricado por Novo Nordisk y basado en el ingrediente activo semaglutida, fue aprobado por la Administracin de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en ingls) en agosto para una enfermedad heptica grave llamada esteatohepatitis asociada a disfuncin metablica, o MASH, que se estima afecta a alrededor del 6 % de los adultos en Estados Unidos
This careful step-up approach minimises digestive side effects and gives your body time to adapt before progressing to therapeutic doses (0.5mg and 1mg) under your doctors guidance
.png)
